~~WHAT IS CLAIMED IS:~~

1. A liquid formulation comprising (a) a polypeptide in an amount of greater than about 50 mg/mL and (b) dimethyl sulfoxide (DMSO) or dimethylacetamide (DMA) in an amount of between about 0.1% to about 50% v/v of the formulation, wherein the formulation has reduced viscosity compared to the same formulation in the absence of DMSO or DMA.

2. The formulation of claim 1, wherein the polypeptide is selected from the group consisting of:

(a) a polypeptide that is capable of forming a secondary structure, tertiary structure, and/or quaternary structure;

(b) a polypeptide that is hydrophobic;

(c) a polypeptide that has a molecular weight of greater than about 5,000 Daltons;

(d) a polypeptide that is a therapeutic polypeptide; and

(e) a polypeptide that is an antibody.

3. The formulation of claim 2 part (a), wherein the polypeptide is selected from the group consisting of:

(a) a polypeptide that is capable of forming a secondary structure; and

(b) a polypeptide that is about 100 amino acids or greater.

4. The formulation of claim 3 part (a), wherein the secondary structure is a β-sheet.

5. The formulation of claim 2 part (e), wherein the antibody is selected from the group consisting of:

(a) a monoclonal antibody; and

(b) an antigen binding fragment.

6. The formulation of claim 5 part (a), wherein the monoclonal antibody is selected from the group consisting of:

(a) a chimeric antibody, humanized antibody, or human antibody; and

(b) an IgG monoclonal antibody.

7. The formulation of claim 5 part (b), wherein the antigen binding fragment is selected from the group consisting of a Fab fragment, a Fab' fragment, a $F(ab')_2$ fragment, a scFv, a Fv, and a diabody.

8. The formulation of claim 1, wherein DMSO or DMA is in an amount of between about 1% to about 10% v/v of the formulation.

9. The formulation of claim 8, wherein DMSO or DMA is in an amount of between about 1% to about 5% v/v of the formulation.

10. The formulation of claim 1, wherein the formulation is selected from the group consisting of:

(a) a formulation that further comprises histidine; and

(b) a formulation that further comprises arginine-HCl.

11. The formulation of claim 10 part (a), wherein histidine is in an amount of between about 10 mM to about 100 mM.

12. The formulation of claim 10 part (b), wherein arginine-HCl is in an amount of between about 50 mM to about 200 mM.

13. The formulation of claim 1, wherein the polypeptide is in an amount of about 100 mg/mL or greater.

14. The formulation of claim 13, wherein the polypeptide is in an amount of between about 100 mg/mL and about 300 mg/mL.

15. The formulation of claim 1, wherein the viscosity is selected from the group consisting of:

(a) a viscosity that is reduced compared to the same formulation in the absence of DMSO or DMA by between about 1 to about 1000 cP;

(b) a viscosity that is reduced compared to the same formulation in the absence of DMSO or DMA by between about 1.2 and about 10 fold; and

(c) a viscosity that is about 50 cP or less.

16. The formulation of claim 15 part (a), wherein the viscosity is reduced compared to the same formulation in the absence of DMSO or DMA by between about 5 to about 100 cP.

17. The formulation of claim 15 part (b), wherein the viscosity is reduced compared to the same formulation in the absence of DMSO or DMA by between about 1.2 and about 5 fold.

18. The formulation of claim 15 part (c), wherein the viscosity is about 25 cP or less.

19. The formulation of claim 1, wherein the pH is between about 5 and about 8.

20. The formulation of claim 19, wherein the pH is between about 5 and about 6.5.

21. The formulation of claim 1, wherein the formulation is formulated for administration by injection.

22. The formulation of claim 21, wherein the formulation is formulated for administration by subcutaneous injection.

23. A method of making the formulation of claim 1 comprising combining the polypeptide and DMSO or DMA.

24. An article of manufacture comprising a container containing the formulation of claim 1.

25. The article of manufacture of claim 24, wherein the container is a syringe.

26. The article of manufacture of claim 25, wherein the syringe is further contained within an injection device.

27. The article of manufacture of claim 26, wherein the injection device is an autoinjector.

28. Use of the formulation of claim 2 part (d) in the manufacture of a medicament for treating a disease or disorder in a subject in need thereof.

29. The use of claim 28, wherein the formulation is to be administered by injection.

30. The use of claim 29, wherein the formulation is to be administered by subcutaneous injection.

31. The use of any one of claims 28 to 30, wherein the disease or disorder is selected from the group consisting of an inflammatory disease, a cell proliferative disorder, a proliferative disorder, and a tumor.

32. The use of claim 31, wherein the cancer is selected from the group consisting of squamous cell cancer, lung cancer, cancer of the peritoneum, hepatocellular cancer, gastric or stomach cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, cancer of the urinary tract, hepatoma, breast cancer, colon cancer, rectal cancer, colorectal cancer, endometrial or uterine carcinoma, salivary gland carcinoma, kidney or renal cancer, prostate cancer, vulval cancer, thyroid cancer, hepatic carcinoma, anal carcinoma, penile carcinoma, melanoma, multiple myeloma, B-cell lymphoma, brain cancer, and head and neck cancer.

33. The formulation of claim 2 part (d) for use in therapy.

WHAT IS CLAIMED IS:

1. A liquid aqueous formulation comprising (a) a antibody in an amount of greater than about 50 mg/mL and (b) dimethyl sulfoxide (DMSO) or dimethylacetamide (DMA) in an amount of between about 0.1 % to about 50% v/v of the formulation, wherein the formulation has reduced viscosity compared to the same formulation in the absence of DMSO or DMA.

2. The formulation of claim 1, wherein the antibody is selected from the group consisting of:
(a) a antibody that is capable of forming a secondary structure, tertiary structure, and/or quaternary structure;
(b) a antibody is hydrophobic;
(c) a antibody has a molecular weight of greater than about 5,000 Daltons; and
(d) a antibody is a therapeutic antibody.

3. The formulation of claim 2 part a, wherein the antibody is selected from the group consisting of:
(a) a antibody capable of forming a secondary structure; and
(b) a antibody is about 100 amino acids or greater.

4. The formulation of claim 3 part (a), wherein the secondary structure is a β-sheet.

5. The formulation of claim 1, wherein the antibody is selected from the group consisting of:
(a) a monoclonal antibody; and
(b) an antigen binding fragment.

6. The formulation of claim 5 part (a), wherein the monoclonal antibody is selected from the group consisting of:
(a) a chimeric antibody, humanized antibody, or human antibody; and
(b) an IgG monoclonal antibody.

7. The formulation of claim 5 part (b), wherein the antigen binding fragment is selected from the group consisting of a Fab fragment, a Fab' fragment, a F(ab')2 fragment, a scFv, a Fv, and a diabody.

8. The formulation of claim 1, wherein DMSO or DMA is in an amount of between about 1% to about 10% v/v of the formulation.

9. The formulation of claim 8, wherein DMSO or DMA is in an amount of between about 1% to about 5% v/v of the formulation.

10. The formulation of claim 1, wherein the formulation is selected from the group consisting of:
(a) a formulation that further comprises histidine; and
(b) a formulation that further comprises arginine-HCl.

11. The formulation of claim 10 part (a), wherein histidine is in an amount of between about 10 mM to about 100 mM.

12. The formulation of claim 10 part (b), wherein arginine-HCl is in an amount of between about 50 mM to about 200 mM.

13. The formulation of claim 1, wherein the antibody is in an amount of about 100 mg/mL or greater.

14. The formulation of claim 1, wherein the antibody is in an amount of between about 100 mg/mL and about 300 mg/mL.

15. The formulation of claim 1, wherein the viscosity is selected from the group consisting of:
(a) a viscosity that is reduced compared to the same formulation in the absence of DMSO or DMA by between about 1 to about 1000 cP;

(b) a viscosity that is reduced compared to the same formulation in the absence of DMSO or DMA by between about 1.2 and about 10 fold; and
(c) a viscosity that is about 50 cP or less.

16. The formulation of claim 15 part (a), wherein the viscosity is reduced compared to the same formulation in the absence of DMSO or DMA by between about 5 to about 100 cP.

17. The formulation of claim 15 part (b), wherein the viscosity is reduced compared to the same formulation in the absence of DMSO or DMA by between about 1.2 and about 5 fold.

18. The formulation of claim 15 part (c), wherein the viscosity is about 25 cP or less.

19. The formulation of claim 1, wherein the pH is between about 5 and about 8.

20. The formulation of claim 19, wherein the pH is between about 5 and about 6.5.

21. The formulation of claim 1, wherein the formulation is formulated for administration by injection.

22. The formulation of claim 21, wherein the formulation is formulated for administration by subcutaneous injection.

23. A method of making the formulation of claim 1 comprising combining the antibody and DMSO or DMA in an aqueous solution.

24. An article of manufacture comprising a container containing the formulation of claim 1.

25. The article of manufacture of claim 24, wherein the container is a syringe.

26. The article of manufacture of claim 25, wherein the syringe is further contained within an injection device.

27. The article of manufacture of claim 26, wherein the injection device is an autoinjector.

28. Use of the formulation of claim 2 part (d) in the manufacture of a medicament for treating a disease or disorder in a subject in need thereof.

29. The use of claim 28, wherein the formulation is to be administered by injection.

30. The use of claim 29, wherein the formulation is to be administered by subcutaneous injection.

31. The use of any one of claims 28 to 30, wherein the disease or disorder is selected from the group consisting of an inflammatory disease, a cell proliferative disorder, a proliferative disorder, a cancer, and a tumor.

32. The use of claim 31, wherein the cancer is selected from the group consisting of squamous cell cancer, lung cancer, cancer of the peritoneum, hepatocellular cancer, gastric or stomach cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, cancer of the urinary tract, hepatoma, breast cancer, colon cancer, rectal cancer, colorectal cancer, endometrial or uterine carcinoma, salivary gland carcinoma, kidney or renal cancer, prostate cancer, vulval cancer, thyroid cancer, hepatic carcinoma, anal carcinoma, penile carcinoma, melanoma, multiple myeloma, B-cell lymphoma, brain cancer, and head and neck cancer.

33. The formulation of claim 2 part (d) for use in therapy.